Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
19.55
+0.05 (0.26%)
At close: May 15, 2026, 4:00 PM EDT
19.58
+0.03 (0.15%)
Pre-market: May 18, 2026, 7:20 AM EDT
Aktis Oncology Revenue
Aktis Oncology had revenue of $3.23M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $8.28M, up 1,394.04% year-over-year. In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth.
Revenue (ttm)
$8.28M
Revenue Growth
+1,394.04%
P/S Ratio
130.56
Revenue / Employee
$104,772
Employees
79
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKTS News
- 4 days ago - Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M - TheFly
- 6 days ago - Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - GlobeNewsWire
- 11 days ago - Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewsWire
- 12 days ago - Aktis Oncology Transcript: Study update - Transcripts
- 13 days ago - Aktis Oncology initiates clinical trial of AKY-25191 - TheFly
- 13 days ago - Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - GlobeNewsWire
- 19 days ago - Aktis Oncology initiated with an Outperform at William Blair - TheFly